Satralizumab

Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2][3].

Product Specifications

CAS Number

[1535963-91-7]

Product Name Alternative

RG-6168; SA-237

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/satralizumab.html

Purity

99.82

Solubility

H2O

Smiles

[Satralizumab]

Molecular Weight

(144.5 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Heydari AH, et al. Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development. Cardiovasc Drugs Ther. 2021 Nov 26. |[2]Duchow A, et al. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag. 2021 Feb;11 (1) :49-59.|[3]Bennett JL, et al. Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12 (5) :e200450.